Search research articles
Contact Us
Filters
Showing results (191-200 of 241) with videos related to
Page
of 25
Sort By:
Cancer Medicine
|
July 18, 2019
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
Emilie Charton, Jean-Baptiste Bachet, Pascal Hammel, et al.
JAMA Oncology
|
September 1, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
Thierry Conroy, Florence Castan, Anthony Lopez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 4, 2013
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
Jean-Baptiste Bachet, Raphael Maréchal, Pieter Demetter, et al.
Journal of the National Cancer Institute
|
February 2, 2015
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial
David Goldstein, Robert Hassan El-Maraghi, Pascal Hammel, et al.
JCO Global Oncology
|
April 23, 2026
Mapping National Definitions, Classifications, and Policy Approaches to Poor-Prognosis Cancers Across the G7 Cancer Initiative Countries
Marisa Nishio, Hiromi Sugiyama, Valerie McCormack, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 11, 2023
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial
Cindy Neuzillet, Olivier Bouché, Christophe Tournigand, et al.
The Journal of Pathology
|
December 22, 2018
Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma
Cindy Neuzillet, Annemilaï Tijeras-Raballand, Chanthirika Ragulan, et al.
British Journal of Cancer
|
September 16, 2015
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Alix Portal, Simon Pernot, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 19, 2022
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies
Julien Edeline, Satoshi Hirano, Aurélie Bertaut, et al.
International Journal of Cancer
|
December 23, 2022
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study
Marie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 241) with videos related to
Sort By:
Page
of 25
Cancer Medicine
|
July 18, 2019
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
Emilie Charton, Jean-Baptiste Bachet, Pascal Hammel, et al.
JAMA Oncology
|
September 1, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
Thierry Conroy, Florence Castan, Anthony Lopez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 4, 2013
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
Jean-Baptiste Bachet, Raphael Maréchal, Pieter Demetter, et al.
Journal of the National Cancer Institute
|
February 2, 2015
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial
David Goldstein, Robert Hassan El-Maraghi, Pascal Hammel, et al.
JCO Global Oncology
|
April 23, 2026
Mapping National Definitions, Classifications, and Policy Approaches to Poor-Prognosis Cancers Across the G7 Cancer Initiative Countries
Marisa Nishio, Hiromi Sugiyama, Valerie McCormack, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 11, 2023
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial
Cindy Neuzillet, Olivier Bouché, Christophe Tournigand, et al.
The Journal of Pathology
|
December 22, 2018
Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma
Cindy Neuzillet, Annemilaï Tijeras-Raballand, Chanthirika Ragulan, et al.
British Journal of Cancer
|
September 16, 2015
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Alix Portal, Simon Pernot, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 19, 2022
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies
Julien Edeline, Satoshi Hirano, Aurélie Bertaut, et al.
International Journal of Cancer
|
December 23, 2022
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study
Marie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, et al.
Page
of 25